A Phase 2 interventional study of Botulinum Neurotoxin Serotype E and Placebo in Abdominoplasty, sponsored by Allergan. Terminated at 2 sites in United States. Open to participants aged 23 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-08-05.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pain by AbbVie — none open to participants now, none under way, none of them phase 3. Pain · AbbVie.
Among the 19 studies in Pain by AbbVie, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 19th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →None of the 19 studies in Pain by AbbVie is open now. The open studies under Pain, anywhere →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 23 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 155 across the 17 interventional studies, 86 across the 2 observational. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Pain by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
Drug: Placebo
Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
Biological: Botulinum Neurotoxin Serotype E
Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
Biological: Botulinum Neurotoxin Serotype E
Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
Biological: Botulinum Neurotoxin Serotype E
Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
Also known as: EB-001, BoNT/E
Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 12 to 96 hours postsurgery
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 0 to 96 hours postsurgery
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 0 to 72 hours postsurgery
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 0 to 48 hours postsurgery
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 0 to 24 hours postsurgery
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
Time frame: Every 2 hours from 12 to 24 hours postsurgery
Participants Overall Assessment of Pain Using the NPRS After Discharge
The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.
Time frame: Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26
Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)
The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately ≥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.
Time frame: 8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge
Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories
The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.
Time frame: Days 5, 8, 15 and 29
Number of Doses of Rescue Medications Used
Time frame: Up to 96 hours postsurgery
| Milestone | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| Started | 12 | 4 | 4 | 3 |
| Completed | 12 | 3 | 4 | 3 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hour (hr)*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96) | 321.18 ± 217.993 | 209.30 ± NA | 415.40 ± 124.101 | 372.53 ± 135.799 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hr*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery | 403.80 ± 229.152 | 282.50 ± NA | 506.83 ± 130.598 | 450.97 ± 139.769 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hr*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72) | 338.91 ± 173.785 | 280.50 ± NA | 416.70 ± 97.464 | 372.47 ± 86.226 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hr*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48) | 253.53 ± 106.862 | 240.80 ± NA | 283.20 ± 60.450 | 274.47 ± 32.686 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hr*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24) | 144.49 ± 46.693 | 149.80 ± NA | 155.53 ± 28.726 | 146.30 ± 21.717 |
The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.
| hr*score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24) | 61.91 ± 32.210 | 76.60 ± NA | 64.10 ± 22.825 | 67.83 ± 18.827 |
The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.
| score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| Day 6 | 2.3 ± 1.66 | 0.0 ± NA | 6.0 ± 1.83 | 2.3 ± 2.08 |
| Day 7 | 2.3 ± 2.78 | 0.0 ± NA | 3.8 ± 0.50 | 3.0 ± 3.00 |
| Day 8 | 1.8 ± 1.79 | 0.0 ± NA | 3.5 ± 1.73 | 3.0 ± 3.00 |
| Day 9 | 2.1 ± 2.62 | 0.0 ± NA | 5.3 ± 1.50 | 1.5 ± 2.12 |
| Day 10 | 1.8 ± 1.92 | 0.0 ± NA | 4.0 ± 0.82 | 1.5 ± 2.12 |
| Day 11 | 1.8 ± 2.28 | 0.0 ± NA | 3.3 ± 1.50 | 1.5 ± 2.12 |
| Day 12 | 1.7 ± 1.87 | 0.0 ± NA | 2.5 ± 1.29 | 1.5 ± 2.12 |
| Day 13 | 1.7 ± 1.73 | 0.0 ± NA | 3.0 ± 0.00 | 2.0 ± 2.83 |
| Day 14 | 1.7 ± 1.94 | 0.0 ± NA | 2.3 ± 1.71 | 2.0 ± 2.83 |
| Day 16 | 1.9 ± 2.47 | 0.0 ± NA | 2.0 ± 0.82 | 1.5 ± 2.12 |
| Day 18 | 1.6 ± 2.26 | 0.0 ± NA | 1.8 ± 0.96 | 1.5 ± 2.12 |
| Day 20 | 1.6 ± 2.20 | 0.0 ± NA | 1.8 ± 0.96 | 1.5 ± 2.12 |
| Day 22 | 1.1 ± 1.73 | 0.0 ± NA | 1.0 ± 1.41 | 1.5 ± 2.12 |
| Day 24 | 1.5 ± 2.45 | 0.0 ± NA | 1.0 ± 1.41 | 2.0 ± 2.83 |
| Day 26 | 1.3 ± 1.98 | 0.0 ± NA | 1.0 ± 1.41 | 1.5 ± 2.12 |
The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately ≥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.
| score on a scale | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| 8 hours after surgery | 6.9 ± 2.74 | 5.0 ± NA | 6.0 ± 2.45 | 6.3 ± 0.58 |
| 16 hours after surgery | 8.7 ± 1.53 | 4.0 ± NA | — | 7.0 ± NA |
| 24 hours after surgery | 6.6 ± 2.40 | 5.0 ± NA | 7.5 ± 1.29 | 6.3 ± 0.58 |
| 30 hours after surgery | 6.5 ± 2.45 | 5.0 ± NA | 7.0 ± 2.16 | 5.0 ± 2.00 |
| 36 hours after surgery | 6.3 ± 1.89 | 4.0 ± NA | 6.5 ± 1.29 | 6.3 ± 0.58 |
| 42 hours after surgery | 5.8 ± 1.47 | — | — | — |
| 48 hours after surgery | 4.3 ± 1.50 | 3.0 ± NA | 5.3 ± 1.71 | 3.7 ± 1.53 |
| 54 hours after surgery | 4.8 ± 1.20 | 2.0 ± NA | 6.3 ± 3.10 | 4.0 ± 2.00 |
| 60 hours after surgery | 6.3 ± 2.75 | 3.0 ± NA | 6.0 ± 1.41 | 3.3 ± 2.52 |
| 66 hours after surgery | 4.7 ± 3.20 | — | — | — |
| 72 hours after surgery | 3.7 ± 2.45 | 0.0 ± NA | 4.0 ± 2.71 | 3.0 ± 1.73 |
| 78 hours after surgery | 3.6 ± 2.62 | 0.0 ± NA | 4.5 ± 2.08 | 3.3 ± 2.08 |
| 84 hours after surgery | 4.5 ± 3.32 | 1.0 ± NA | 5.0 ± 1.15 | 3.0 ± 2.65 |
| 96 hours after surgery | 2.4 ± 1.81 | 0.0 ± NA | 3.5 ± 1.29 | 3.3 ± 3.06 |
| Day 8 after discharge | 2.1 ± 2.20 | 1.0 ± NA | 4.8 ± 1.71 | 3.3 ± 3.06 |
| Day 15 after discharge | 1.6 ± 1.77 | 0.0 ± NA | 3.8 ± 2.99 | 2.7 ± 2.31 |
| Day 29 after discharge | 1.5 ± 1.97 | — | 0.5 ± 0.58 | 0.0 ± NA |
The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.
| Participants | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| Day 5 — PGA score 3 | 7 | 1 | 2 | 1 |
| Day 5 — PGA score 2 | 4 | 0 | 2 | 1 |
| Day 5 — PGA score 1 | 0 | 0 | 0 | 1 |
| Day 5 — PGA score 0 | 0 | 0 | 0 | 0 |
| Day 8 — PGA score 3 | 7 | 1 | 0 | 1 |
| Day 8 — PGA score 2 | 4 | 0 | 2 | 0 |
| Day 8 — PGA score 1 | 0 | 0 | 1 | 2 |
| Day 8 — PGA score 0 | 0 | 0 | 1 | 0 |
| Day 15 — PGA score 3 | 8 | 1 | 2 | 1 |
| Day 15 — PGA score 2 | 3 | 0 | 1 | 1 |
| Day 15 — PGA score 1 | 0 | 0 | 1 | 1 |
| Day 15 — PGA score 0 | 0 | 0 | 0 | 0 |
| Day 29 — PGA score 3 | 9 | 1 | 3 | 1 |
| Day 29 — PGA score 2 | 2 | 0 | 1 | 2 |
| Day 29 — PGA score 1 | 0 | 0 | 0 | 0 |
| Day 29 — PGA score 0 | 0 | 0 | 0 | 0 |
| doses | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| Oxycodone | 9.7 ± 5.92 | 5.0 ± NA | 11.8 ± 5.68 | 11.7 ± 4.93 |
| Opioid | 14.2 ± 7.40 | 8.0 ± NA | 15.8 ± 6.90 | 16.0 ± 6.08 |
Collected over Up to 31 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Botulinum Neurotoxin Serotype E Dose 1 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Botulinum Neurotoxin Serotype E Dose 2 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Botulinum Neurotoxin Serotype E Dose 3 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/12 | 1/4 | 2/4 | 2/3 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/12 | 0/4 | 0/4 | 2/3 |
| ConstipationGastrointestinal disorders | 2/12 | 1/4 | 2/4 | 0/3 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 0/4 | 2/4 | 0/3 |
| HeadacheNervous system disorders | 5/12 | 1/4 | 1/4 | 0/3 |
| RashSkin and subcutaneous tissue disorders | 2/12 | 0/4 | 0/4 | 1/3 |
| VomitingGastrointestinal disorders | 1/12 | 1/4 | 1/4 | 0/3 |
| DyspepsiaGastrointestinal disorders | 0/12 | 0/4 | 1/4 | 0/3 |
| PruritusSkin and subcutaneous tissue disorders | 0/12 | 1/4 | 1/4 | 0/3 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 0/12 | 1/4 | 0/4 | 0/3 |
Safety Population included all participants exposed to any amount of study drug.
| Age, Continuous(years) | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 | Total |
|---|---|---|---|---|---|
| Mean | 36.5 ± 5.2 | 33.0 ± 6.38 | 36.3 ± 7.72 | 41.0 ± 14.0 | 36.7 ± 3.29 |
| Sex: Female, Male(Participants) | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 | Total |
|---|---|---|---|---|---|
| Female | 11 | 4 | 4 | 3 | 22 |
| Male | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 5 | 3 | 1 | 2 | 11 |
| White or Caucasian | 6 | 1 | 2 | 1 | 10 |
| Other/Mixed | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Botulinum Neurotoxin Serotype E Dose 1 | Botulinum Neurotoxin Serotype E Dose 2 | Botulinum Neurotoxin Serotype E Dose 3 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 1 | 2 | 1 | 10 |
| Not Hispanic or Latino | 6 | 3 | 2 | 2 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2018 to primary completion in Jul 2018, 2 months.
Results were first posted in Aug 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type E